請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66385完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林峰輝 | |
| dc.contributor.author | Wei-Yu Chen | en |
| dc.contributor.author | 陳韋佑 | zh_TW |
| dc.date.accessioned | 2021-06-17T00:33:15Z | - |
| dc.date.available | 2017-03-19 | |
| dc.date.copyright | 2012-03-19 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2012-02-08 | |
| dc.identifier.citation | Reference
1. Reginster, J.Y., The prevalence and burden of arthritis. Rheumatology (Oxford), 2002. 41 Supp 1: p. 3-6. 2. McDougall, J.J., Pain and OA. J Musculoskelet Neuronal Interact, 2006. 6(4): p. 385-6. 3. Creamer, P., Osteoarthritis pain and its treatment. Curr Opin Rheumatol, 2000. 12(5): p. 450-5. 4. Brundtland, G.H., A WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium met in Geneva from 13 to 15 January 2000. Burden of Musculoskeletal Conditions at the Start of the New Millennium, 2003. 919: p. 1-218. 5. Yamada, H., Sugimoto, H., Terada, N., Kanaji, A., Kato, S., Date, H., Ichinose, H., Miyazaki, K., Intraarticular injection of high molecular weight hyaluronan for osteoarthritis of the knee - Prediction of effectiveness with biological markers. Journal of Rheumatology, 2006. 33(12): p. 2527-2531. 6. Neustadt, D., Caldwell, J., Bell, M., Wade, J., Gimbel, J., Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc (R)) in osteoarthritis of the knee: A randomized, controlled, multicenter trial. Journal of Rheumatology, 2005. 32(10): p. 1928-1936. 7. Pagnano, M. and G. Westrich, Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthritis Cartilage, 2005. 13(9): p. 751-61. 8. Kotevoglu, N., Iyibozkurt, P. C., Hiz, O., Toktas, H., Kuran, B., A prospective randomised controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int, 2006. 26(4): p. 325-30. 9. Lee, P.B., Kim, Y. C., Lim, Y. J., Lee, C. J., Sim, W. S., Ha, C. W., Bin, S. I., Lim, K. B., Choi, S. S., Lee, S. C., Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: Open-label, randomized, multicentre clinical trial. Journal of International Medical Research, 2006. 34(1): p. 77-87. 10. Kirchner, M. and D. Marshall, A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage, 2006. 14(2): p. 154-162. 11. Henrotin, Y.E., P. Bruckner, and J.P. Pujol, The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage, 2003. 11(10): p. 747-55. 12. Franzoso, G., Bubici, C., Papa, S., Dean, K., Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 2006. 25(51): p. 6731-6748. 13. Winrow, V.R., Winyard, P. G., Morris, C. J., Blake, D. R., Free radicals in inflammation: second messengers and mediators of tissue destruction. Br Med Bull, 1993. 49(3): p. 506-22. 14. Sutipornpalangkul, W., N.P. Morales, and T. Harnroongroj, Free radicals in primary knee osteoarthritis. J Med Assoc Thai, 2009. 92 Suppl 6: p. S268-74. 15. Meyer, K. and J.W. Palmer, The polysaccharide of the vitreous humor. Journal of Biological Chemistry, 1934. 107(3): p. 629-634. 16. Toole, B.P., Hyaluronan is not just a goo! Journal of Clinical Investigation, 2000. 106(3): p. 335-6. 17. Roden L. Structure and metabolism of connective tissue proteoglycans. In: Lennarz W J, ed. The biochemistry of glycoproteins and proteoglycans. New York: Plenum Publ., 1980; 267-371.) 18. http://en.wikipedia.org/wiki/File:Hyaluronan.png 19. Knudson, C.B. and W. Knudson, Hyaluronan and CD44: modulators of chondrocyte metabolism. Clin Orthop Relat Res, 2004(427 Suppl): p. S152-62. 20. Nagano, O. and H. Saya, Mechanism and biological significance of CD44 cleavage. Cancer Sci, 2004. 95(12): p. 930-5. 21. Fraser, J.R., T.C. Laurent, and U.B. Laurent, Hyaluronan: its nature, distribution, functions and turnover. J Intern Med, 1997. 242(1): p. 27-33. 22. D.J. McCarty, Synovial fluid, in: Arthritis and Allied Conditions. A Textbook of Rheumatology, D.J. McCarty and W.J. Koopman, eds, Vol. 1, 13th edn, Williams & Wilkins, Baltimore, 1997, pp. 81–99. 23. Gossec, L. and M. Dougados, Do intra-articular therapies work and who will benefit most? Best Practice & Research in Clinical Rheumatology, 2006. 20(1): p. 131-144. 24. Vitanzo, PC Jr,. Sennett, BJ.,Hyaluronans: is clinical effectiveness dependent on molecular weight?. Am J Orthop. 2006 Sep;35(9):421-8. 25. Wang, C.T., Lin, Y. T., Chiang, B. L., Lin, Y. H., Hou, S. M., High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage, 2006. 14(12): p. 1237-47. 26. Fioravanti, A., Cantarini, L., Chellini, F., Manca, D., Paccagnini, E., Marcolongo, R., Collodel, G.,Effect of hyaluronic acid (MW 500-730 kDa) on proteoglycan and nitric oxide production in human osteoarthritic chondrocyte cultures exposed to hydrostatic pressure. Osteoarthritis Cartilage, 2005. 13(8): p. 688-96. 27. Karatay, S., Kiziltunc, A., Yildirim, K., Karanfil, R. C., Senel, K., Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis. Clinical Rheumatology, 2005. 24(5): p. 497-501. 28. Huang, M.H., Chen, C. H., Chen, T. W., Weng, M. C., Wang, W. T., Wang, Y. L., The effects of weight reduction on the rehabilitation of patients with knee osteoarthritis and obesity. Arthritis Care and Research, 2000. 13(6): p. 398-405. 29. Childs, J.D., Cleland, J. A., Elliott, J. M., Teyhen, D. S., Wainner, R. S., Whitman, J. M., Sopky, B. J., Godges, J. J., Flynn, T. W., Neck pain: Clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American physical therapy association (vol 38, pg A1, 2008). Journal of Orthopaedic & Sports Physical Therapy, 2009. 39(4): p. 297-297. 30. Zhang, W., A. Jones, and M. Doherty, Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis, 2004. 63(8): p. 901-7. 31. Wolfe, M.M., D.R. Lichtenstein, and G. Singh, Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med, 1999. 340(24): p. 1888-99. 32. Leopold, S.S., Redd, B. B., Warme, W. J., Wehrle, P. A., Pettis, P. D., Shott, S., Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J Bone Joint Surg Am, 2003. 85-A(7): p. 1197-203. 33. Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R., Wells, G., Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev, 2005(2): p. CD005321. 34. Wobig, M., Dickhut, A., Maier, R., Vetter, G., Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther, 1998. 20(3): p. 410-23. 35. Altman, R.D. and R. Moskowitz, Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. Journal of Rheumatology, 1998. 25(11): p. 2203-12. 36. Wen, D.Y., Intra-articular hyaluronic acid injections for knee osteoarthritis. Am Fam Physician, 2000. 62(3): p. 565-70, 572. 37. Peat, G., R. McCarney, and P. Croft, Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Annals of the Rheumatic Diseases, 2001. 60(2): p. 91-97. 38. Neustadt DH.,Current approach to therapy for osteoarthritis of the knee. Louisville Med 2004;51:341-3. 39. Hospitalizations for Osteoarthritis Rising Sharply Newswise, Retrieved on September 4, 2008. 40. Merx, H., Dreinhofer, K., Schrader, P., Sturmer, T., Puhl, W., Gunther, K. P., Brenner, H l., International variation in hip replacement rates. Ann Rheum Dis, 2003. 62(3): p. 222-6. 41. NIH Consensus Statement on total knee replacement December 8-10, 2003. J Bone Joint Surg Am, 2004. 86-A(6): p. 1328-35. 42. Felson, D.T., Clinical practice. Osteoarthritis of the knee. N Engl J Med, 2006. 354(8): p. 841-8. 43. Lohmander, L.S. and D. Felson, Can we identify a 'high risk' patient profile to determine who will experience rapid progression of osteoarthritis? Osteoarthritis Cartilage, 2004. 12 Suppl A: p. S49-52. 44. Sharma, L., Cahue, S., Song, J., Hayes, K., Pai, Y. C., Dunlop, D., Physical functioning over three years in knee osteoarthritis: role of psychosocial, local mechanical, and neuromuscular factors. Arthritis and Rheumatism, 2003. 48(12): p. 3359-70. 45. Sharma, L., Song, J., Felson, D. T., Cahue, S., Shamiyeh, E., Dunlop, D. D., The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA, 2001. 286(2): p. 188-95. 46. Buckland-Wright, J.C., J.A. Lynch, and D.G. Macfarlane, Fractal signature analysis measures cancellous bone organisation in macroradiographs of patients with knee osteoarthritis. Ann Rheum Dis, 1996. 55(10): p. 749-55. 47. Burr DB. Subchondral bone. In: Brandt KD, Lomander S, Doherty M (eds). Osteoarthritis. Oxford University Press, Oxford, UK; 1998:144-156. 48. Li, B. and R.M. Aspden, Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis. Ann Rheum Dis, 1997. 56(4): p. 247-54. 49. Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J., Stitt, L. W., Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Journal of Rheumatology, 1988. 15(12): p. 1833-40. 50. Wieland, H.A., Michaelis, M., Kirschbaum, B. J., Rudolphi, K. A., Osteoarthritis - an untreatable disease? Nat Rev Drug Discov, 2005. 4(4): p. 331-44. 51. Altman, R., Brandt, K., Hochberg, M., Moskowitz, R., Bellamy, N., Bloch, D. A., Buckwalter, J., Dougados, M., Ehrlich, G., Lequesne, M., Lohmander, S., Murphy, W. A., Jr., Rosario-Jansen, T., Schwartz, B., Trippel, S., Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage, 1996. 4(4): p. 217-43. 52. Goldberg, V.M. and J.A. Buckwalter, Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage, 2005. 13(3): p. 216-24. 53. Peat, G., R. McCarney, and P. Croft, Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Annals of the Rheumatic Diseases, 2001. 60(2): p. 91-97. 54. Felson, D.T. and Y.Q. Zhang, An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis and Rheumatism, 1998. 41(8): p. 1343-1355. 55. Bullough P. Pathology of osteoarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. Edinburgh: Mosby, 2003:1835–45. 56. Loeuille, D., Toussaint, F., Champigneulles, J., Grossin, L., Blum, A., Chary-Valckenaere, I., Netter, P., Gillet, P.,MR evaluation of synovial inflammation in knee OA: Histological correlation. Arthritis and Rheumatism, 2002. 46(9): p. S566-S567. 57. Pelletier, J.P., J. Martel-Pelletier, and S.B. Abramson, Osteoarthritis, an inflammatory disease - Potential implication for the selection of new therapeutic targets. Arthritis and Rheumatism, 2001. 44(6): p. 1237-1247. 58. Pelletier, J.P., Mccollum, R., Cloutier, J. M., Martelpelletier, J., Synthesis of Metalloproteases and Interleukin-6 (Il-6) in Human Osteoarthritic Synovial-Membrane Is an Il-1 Mediated Process. Journal of Rheumatology, 1995. 22: p. 109-114. 59. Malemud, C.J., N. Islam, and T.M. Haqqi, Pathophysiological mechanisms in Osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs, 2003. 174(1-2): p. 34-48. 60. MW Hungerford, MA Mont, DS Hungerford. Nonoperative treatment of knee arthritis. In: JN Insall and WN Scott, Editors. Surgery of the knee. 3rd edition. New York: Churchill Livingstone; 2001. p. 565-587. 61. Simon, T.M. and D.W. Jackson, Articular cartilage: Injury pathways and treatment options. Sports Medicine and Arthroscopy Review, 2006. 14(3): p. 146-154. 62. Qiu, B., Liu, S. Q., Peng, H., Wang, H. B., The effects of sodium hyaluronate on mRNA expressions of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in cartilage and synovium of traumatic osteoarthritis model. Chin J Traumatol, 2005. 8(1): p. 8-12. 63. Blake, D.R., R.E. Allen, and J. Lunec, Free-Radicals in Biological-Systems - a Review Orientated to Inflammatory Processes. British Medical Bulletin, 1987. 43(2): p. 371-385. 64. Henrotin, Y., B. Kurz, and T. Aigner, Oxygen and reactive oxygen species in cartilage degradation: friends or foes? Osteoarthritis and Cartilage, 2005. 13(8): p. 643-654. 65. Haddad, J.J., Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cellular Signalling, 2002. 14(11): p. 879-897. 66. Afonso, V., Champy, R., Mitrovic, D., Collin, P., Lomri, A., Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine, 2007. 74(4): p. 324-9. 67. Naylor, S., Mason, R. P., Sanders, J. K., Williams, D. H., Moneti, G., Formaldehyde adducts of glutathione. Structure elucidation by two-dimensional n.m.r. spectroscopy and fast-atom-bombardment tandem mass spectrometry. Biochem J, 1988. 249(2): p. 573-9. 68. Pompella, A., Visvikis, A., Paolicchi, A., De Tata, V., Casini, A. F., The changing faces of glutathione, a cellular protagonist. Biochemical Pharmacology, 2003. 66(8): p. 1499-1503. 69. Kirwan, J., Is there a place for intra-articular hyaluronate in osteoarthritis of the knee? Knee, 2001. 8(2): p. 93-101. 70. G. W. Scott Blair. An Introduction to Biorheology,(Elsevier Scientific Publishing Company,Amsterdam 1974) (see Chapt. VIII). 71. Dowson D. Modes of lubrication in humanjoints, Proc. Instn. Mech. Engrs. 181, pt. 3F, paper 12(1966-67). 72. Seller, P.C., Dowson, D. and Wright, V., The rheology of synovial fluid. Rheol . Acta. 10 (1971), 2-7. 73. Dintenfass, L., Lubrication in Synovial Joints - a Theoretical Analysis - a Rheological Approach to the Problems of Joint Movements and Joint Lubrication. Journal of Bone and Joint Surgery-American Volume, 1963. 45(6): p. 1241-1256. 74. Caygill, J.C. and G.H. West, The rheological behavior of synovial fluid and its possible relation to joint lubrication. Med Biol Eng, 1969. 7(5): p. 507-16. 75. Sakkas, L.I., Scanzello, C., Johanson, N., Burkholder, J., Mitra, A., Salgame, P., Katsetos, C. D., Platsoucas, C. D., T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. Clinical and Diagnostic Laboratory Immunology, 1998. 5(4): p. 430-437. 76. Moos, V., Fickert, S., Muller, B., Weber, U., Sieper, J., Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. Journal of Rheumatology, 1999. 26(4): p. 870-879. 77. Hiramitsu, T., Yasuda, T., Ito, H., Shimizu, M., Julovi, S. M., Kakinuma, T., Akiyoshi, M., Yoshida, M., Nakamura, T., Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology (Oxford), 2006. 45(7): p. 824-32. 78. Westacott, C.I., Barakat, A. F., Wood, L., Perry, M. J., Neison, P., Bisbinas, I., Armstrong, L., Millar, A. B., Elson, C. J., Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis and Cartilage, 2000. 8(3): p. 213-221. 79. Martel-Pelletier, J., Pathophysiology of osteoarthritis. Osteoarthritis Cartilage, 2004. 12 Suppl A: p. S31-3. 80. Nishimoto, N., Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol, 2006. 18(3): p. 277-81. 81. Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X. F., Achong, M. K., IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. Journal of Clinical Investigation, 1998. 101(2): p. 311-320. 82. Okada, Y., H. Nagase, and E.D. Harris, A Metalloproteinase from Human Rheumatoid Synovial Fibroblasts That Digests Connective-Tissue Matrix Components - Purification and Characterization. Journal of Biological Chemistry, 1986. 261(30): p. 14245-14255. 83. Wu J-J, Lark MW, Chun LE, Eyre DR. , Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. Journal of Biological Chemistry, 1991. 266(9): p. 5625-8. 84. Chakraborti, S., Mandal, M., Das, S., Mandal, A., Chakraborti, T., Regulation of matrix metalloproteinases: An overview. Molecular and Cellular Biochemistry, 2003. 253(1-2): p. 269-285. 85. Dean, D.D. and J.F. Woessner, Jr., Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J, 1984. 218(1): p. 277-80. 86. Pearle, A.D., R.F. Warren, and S.A. Rodeo, Basic science of articular cartilage and osteoarthritis. Clin Sports Med, 2005. 24(1): p. 1-12. 87. Dean, D.D., Martel-Pelletier, J., Pelletier, J. P., Howell, D. S., Woessner, J. F., Jr., Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest, 1989. 84(2): p. 678-85. 88. Pelletier, J.P., Mineau, F., Faure, M. P., Martelpelletier, J., Imbalance between the Mechanisms of Activation and Inhibition of Metalloproteases in the Early Lesions of Experimental Osteoarthritis. Arthritis and Rheumatism, 1990. 33(10): p. 1466-1476. 89. Takahashi, K., Goomer, R. S., Harwood, F., Kubo, T., Hirasawa, Y., Amiel, D., The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1 beta (IL-1 beta), and tissue inhibitor of metalloproteinase-1(TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis and Cartilage, 1999. 7(2): p. 182-190. 90. Shimizu M, Yasuda T, Nakagawa T, Yamashita E,Julovi SM, Hiramitsu T, Nakamura, T.,Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol, 2003. 30(6): p. 1164-72. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66385 | - |
| dc.description.abstract | 退化性關節炎在近年來，被認為是一種非典型的發炎疾病。而穀胱甘肽是一種擁有抗發炎效果的強抗氧化劑，可以保護細胞免受活性氧如自由基和過氧化物的傷害。本論文的目的為探討玻尿酸加入穀胱甘肽對於體外退化性關節炎模式之影響。將0.1mg/ml 的玻尿酸混合不同濃度的穀胱甘肽(5%, 10% 及 20%)，然後作用於從退化性關節炎的病人身上所取出的滑囊細胞，並由即時聚合酶鏈鎖反應檢測與退化性關節炎相關的基因，包括TNF-α, IL-6, MMP-3 和 TIMP-1之基因表現差異。結果發現玻尿酸混合20%穀胱甘肽可以降低一些對關節不好的降解性基因的表現，例如： TNF-α，MMP3。此外，混合20%穀胱甘肽的玻尿酸可以促進對關節有益的基因表現，例如：IL-6，TIMP-1。經由實驗結果，我們認為玻尿酸混合穀胱甘肽作為關節內注射劑有可能可以應用於減輕退化性關節炎之症狀。 | zh_TW |
| dc.description.abstract | Osteoarthritis (OA) is recently recognized as a “non-classical” inflammatory disease. Glutathione (GSH), an antioxidant, has been shown to have an anti-inflammatory effect on protecting cells from reactive oxygen species such as free radicals and peroxides. This study is to examine the effects of hyaluronic acid (HA) supplemented with GSH on expression of four OA-related factors in fibroblast-like synoviocytes (FLSs) from five patients with OA. 0.1mg/ml of HA (Ostenil®) supplemented with different weight percent (5%, 10% and 20%) GSH were co-cultured with FLSs. The gene expression and protein production of OA-related factors, such as TNF-α, IL-6, MMP-3 and TIMP-1 were evaluated by real-time quantitative PCR. The gene expression of TNF-α and MMP-3 were found decreased significantly in every group. TIMP-1 was increased when HA supplemented with GSH in weight percent 5% and 20%. HA supplemented with GSH in weight percent 20% has showed significantly effect on regulating these factors. It had attenuated TNF-α, MMP-3 and up-regulated TIMP-1, IL-6 mRNA expression. We suggest that intra-articular injection of HA supplemented with GSH may be feasible for relieve symptoms of knee osteoarthritis. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T00:33:15Z (GMT). No. of bitstreams: 1 ntu-100-R98548015-1.pdf: 1486809 bytes, checksum: c08a2744bc3996b45ddec4ca84029738 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 口試委員會審定書…………………………………………..……………………………………. I
Acknowledgement…………………………………..……………………………….……………. II 中文摘要.......................................................................................................................................... III Abstract ........................................................................................................................................... IV Table of Contents ............................................................................................................................. V List of Figures …………………………………………………………………………...……..... VIII List of Tables ……………………………………………………………..……...........……...…… X Chapter 1 Introduction ...................................................................................................................... 1 1.1 Foreword ..................................................................................................................................... 1 1.2 Hyaluronic acid ………............................................................................................................... 3 1.3 Multiple effects of HA................................................................................................................. 5 1.4 Biological effects of HA.............................................................................................................. 6 1.5 Current treatments........................................................................................................................ 8 1.6 HA in osteoarthritis ……............................................................................................................ 11 1.7 Disease-modifying activity of HA in the treatment of OA……................................................. 13 1.8 Fibroblast-like synoviocyte (FLS).............................................................................................. 15 Chapter 2 Theoretical Basis ............................................................................................................. 16 2.1 The therapeutic effect of HA through: synovium or cartilage? ................................................. 16 2.2 Free radicals in osteoarthritis ..................................................................................................... 18 2.3 Glutathione ................................................................................................................................ 21 2.4 Anti-inflammatory effect or chondro-protective effect? ........................................................... 23 2.5 The purpose of this thesis………………………………..……………………………………. 24 Chapter 3 Materials and Methods ................................................................................................... 25 3.1 Experimental setup .................................................................................................................... 25 3.2 List of materials and devices ..................................................................................................... 26 3.3 Primary culture of fibroblast-like synoviocyte.......................................................................... 28 3.4 Glutathione supplement to hyaluronic acid ……….................................................................. 29 3.5 OA-induced cytotoxicity and treatment of HA supplemented with GSH…………................. 30 3.6 Viscosity …………………………………………………....................................................... 31 3.7 Real-time Quantitative Polymerase Chain Reaction ……….................................................... 32 Chapter 4 Results…………………………………………………………………………………. 33 4.1 Viscosity…………………………………………………………….………..………………. 33 4.2 Immunocytochemistry staining……………………………...…………………...…………... 34 4.3 Real-time Quantitative PCR .................................................................................................... 35 4.3.1 Effect of GSH and HA on mRNA expression of inflammatory-related cytokines TNF-α and IL-6…………………………..………………………….………….…..…………………… 35 4.3.2 Effect of GSH and HA on mRNA expression of TIMP-1 and MMP-3…………………… 37 Chapter 5 Discussions .................................................................................................................. 39 Chapter 6 Conclusion ................................................................................................................... 43 References .................................................................................................................................... 44 LIST OF FIGURES Chapter 1 Figure 1 Chemical structure of hyaluronan .................................................................................. 3 Figure 2 Intra-articular injection of knee joint ………………………………………………… 10 Figure 3 Articular structures that are affected in osteoarthritis ……………...……….…..……. 12 Chapter 2 Figure 4 Main zones of articular cartilage organization ……………………….……………..... 17 Figure 5 Implication of ROS in cartilage degradation and related synovium inflammatory reaction ……………………………………………………………………....…. 19 Figure 6 Pathways for the production and the removal of superoxide radicals …...................... 20 Figure 7 Chemical structure of glutathione (GSH)………………….…………….…………… 21 Chapter 3 Figure 8 Schematic illustration of the experimental setup………………………………...…… 25 Chapter 4 Figure 9 FLS stained with prolyl-4-hydroxylase (green) and DAPI (blue)................................. 34 Figure 10 FLS stained with prolyl-4-hydroxylase (green) and bright field image under confocal microscope.……………………………………………………………...…...... 34 Figure 11 Effect of HA (0.1mg/ml) supplemented with GSH on FLS (a) TNF-α and (b) IL-6 mRNA expression ………………….…………………………………………..…. 36 Figure 12 Effects of HA (0.1mg/ml) supplemented with GSH on (a) MMP-3, (b) TIMP-1 mRNA expression …………………………………………….…….……………... 38 LIST OF TABLES Table 1 Potential disease-modifying activities of HA ................................................................. 13 Table 2 Preclinical animal models of OA: disease-modifying effects of HA ……..…............... 14 Table 3 List of product names and catalog number……………………….……..….….............. 26 Table 4 The content of culture medium for porcine chondrocytes (per 1 liter) ………………... 27 Table 5 The content of phosphate buffer saline (PBS) ..............................................….............. 27 Table 6 Groups’ abbreviation and description ………………………..………….…....……….. 30 Table 7 Viscosity of HA supplemented with GSH ………………………….….……..……….. 33 | |
| dc.language.iso | en | |
| dc.subject | 滑囊細胞 | zh_TW |
| dc.subject | 退化性關節炎 | zh_TW |
| dc.subject | 玻尿 | zh_TW |
| dc.subject | 酸 | zh_TW |
| dc.subject | 穀胱甘肽 | zh_TW |
| dc.subject | Glutathione (GSH) | en |
| dc.subject | Osteoarthritis (OA) | en |
| dc.subject | Hyaluronic acid (HA) | en |
| dc.subject | Fibroblast-like synoviocytes (FLSs) | en |
| dc.title | 評估玻尿酸與穀胱甘肽於退化性膝關節炎滑囊細胞的影響 | zh_TW |
| dc.title | The Effect of Glutathione-Supplemented Hyaluronan on Osteoarthritis Synoviocytes | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊禎明,郭士民,姚俊旭,趙本秀 | |
| dc.subject.keyword | 退化性關節炎,玻尿,酸,穀胱甘肽,滑囊細胞, | zh_TW |
| dc.subject.keyword | Osteoarthritis (OA),Hyaluronic acid (HA),Glutathione (GSH),Fibroblast-like synoviocytes (FLSs), | en |
| dc.relation.page | 53 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-02-09 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| 顯示於系所單位： | 醫學工程學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 1.45 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。